Global Breast Cancer Immunotherapy Market and Clinical Trials Forecast 2028

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global Breast Cancer Immunotherapy Market and Clinical Trials Forecast 2028 Report Highlights:

Global Breast Cancer Immunotherapy Market Opportunity > USD 60 Billion By 2028
Global Market and Regional Market Trends
Global Market Forecast Till 2028
Approved Drugs Yearly and Quarterly Sales Insight 2019 – 2023
Approved Drugs Global and Regional Sales Insight 2019 – 2023
Approved Drug Pricing and Dosage Analysis
Comprehensive Insight On 250 Drugs In Clinical Trials By Company, Country, Patent
Clinical Insight On More Than 20 Approved Biosimilars and Branded Drugs
Competitive Landscape

With scientific progress, pharmaceutical research and development activities have led to the generation of novel and innovative therapies, which are creating a new era for cancer treatment. Immunotherapy is one such approach that has been around for years but only recently, researchers have been actively working on determing its therapeutic potential. Continuous innovation in breast cancer treatment has enabled the breakthrough of several novel immunotherapeutic approaches.

While conventional methods like surgery and chemotherapy have become primary therapeutic options, their long lasting side effects and growing possibility of developing drug resistance and cancer recurrence have called for the development of more effective treatment options. The introduction of immunotherapy, particularly immune checkpoint inhibitors has transformed the treatment for breast cancer, with immunotherapy being effective even in aggressive forms of breast cancer such as triple negative breast cancer.

The growing demand for therapies having minimal adverse effects, improved drug development, increasing cancer incidence and growing adoption to cancer immunotherapy above other available treatment options are key factors which are propelling the growth of the market. Moreover, with approved immunotherapeutic drugs for breast cancer showing robust sales has been another factor which has resulted in growing number of investments in the market.

Keytruda, developed by Merck has been a “blockbuster” immune checkpoint inhibitor approved for breast cancer. Since, its approval, the immunotherapy drug has only witnessed an exponential growth in its annual sales. Moreover, Merck has also played strategically by introducing several combinations of this blockbuster immunotherapy drug with other treatments, creating a wider range of patient population choosing Keytruda over other methods.

It can be said that immune checkpoint inhibitors have been a vital factor that have resulted the growing market of breast cancer immunotherapy. Following Keytruda, several companies have launched their respective immune checkpoint blockers; however, none has had higher success than Keytruda. The improved understanding about immune evasion by cancer cells and the development of antibodies towards tumor associated antigens have led to the enhanced growth observed in immunotherapy for breast cancer.

Additionally, moving beyond immune checkpoint inhibitors, the market of breast cancer immunotherapy is also witnessing a rise in novel treatment approaches. For instance, several pharmaceutical companies have been transforming different novel immunotherapy options for breast cancer treatment, like bispecific antibodies, oncolytic viruses, cancer vaccines, tumor infiltrating lymphocyte therapy and cell and gene therapies. While some of these methods have has huge impact of hematological malignancies, pharmaceutical companies are not investigating their potential therapeutic application for breast treatment.

For the last two decades, monoclonal antibody based therapies have brought in incredible changes in the field of breast cancer treatment, however, over time with the surge of bispecific antibodies, several clinical trials are evaluating their therapeutic potential in breast cancer. The possibility of engaging the immune system while simultaneously targeting tumor specific antigens is expected to generate a more robust immune response. For the future, it is easily predictable that bispecific antibodies will change the treatment landscape for breast cancer immunotherapy.

Another immunotherapeutic approach that is currently gardening significant attention for researchers all over the world is tumor infiltrating lymphocyte (TIL) therapy. Studies have shown that TILs are one of the strongest biomarkers present specifically for triple negative breast cancer patients and could also possibly be factors resulting in positive prognosis of the disease. Hence, as we move towards immunotherapy for breast cancer, evaluation of tumor infiltrating lymphocytes could be a very affordable ad well as valuable approach that can be combined with already existing or newly emerging techniques.

Additionally, the involvement of academic institutions and research centers has also played a significant role in transforming the global market of breast cancer immunotherapy. Collaborating between pharmaceutical companies as well as academic instructions has been driving innovation in the field, creating a robust portfolio of immunotherapy candidates in the market. With increasing breast cancer incidence, there also grows a significant need to develop more effective therapeutic approaches and the onset of immunotherapy has offered a promising future.

Our report provides an in depth analysis about the commercially available breast cancer immunotherapy drugs. The report describes the current market of breast cancer immunotherapy with insights on the market growth while also highlighting impact on regional sales, pricing, dosage and patent expiration dates. Moreover, the report also includes new trends in the breast cancer immunotherapy market, information about company collaborations, partnerships.

Need For Breast Cancer Immunotherapy?

1.1 Overview

1.2 Breast Cancer Immunotherapy Mechanism Of Action

1.3 Potential Breast Cancer Biomarkers

Global Breast Cancer Immunotherapy Market Overview

2.1 Breast Cancer Global Market Insight: Yearly and Quarterly Sales (2019 – 2023)

2.2 Global Breast Cancer Immunotherapy Market Future Outlook (2023 – 2028)

Global Breast Cancer Immunotherapy Trend Analysis

3.1 US

3.2 UK

3.3 Canada

3.4 Europe

3.4.1 Germany

3.4.2 France

3.4.3 Italy

3.4.4 Spain

3.4.5 Poland

3.4.6 Belgium

3.5 Australia

3.6 China

3.7 Japan

3.8 South Korea

3.9 India

Global Breast Cancer Immunotherapy Approved Drugs Sales, Price, Dosage and Patent Analysis

4.1 Keytruda (Pembrolizumab)

4.2 Perjeta (Pertuzumab)

4.3 Kadcyla (Ado-Trastuzumab Emtansine)

4.4 Phesgo (pertuzumab trastuzumab hyaluronidase)

4.5 Trodelvy (Sacituzumab Govitecan)

4.6 Herceptin (Trastuzumab)

4.7 Enhertu (Fam-Trastuzumab Deruxtecan)

4.8 Margenza (Margetuximab)

4.9 Tecentriq (Atezolizumab)

4.10 Avastin (Bevacizumab)

Global Breast Cancer Immunotherapies Clinical Trials Insight

5.1 By Biomarker

5.2 By Company

5.3 By Country

5.4 By Patient Segment

5.5 By Phase

Global Breast Cancer Immunotherapies Clinical Trials By Company, Country and Indication

6.1 Research

6.2 Preclinical

6.3 Phase-I

6.4 Phase-I/II

6.5 Phase-II

6.6 Phase-II/III

6.7 Phase-III

6.8 Preregistration

6.9 Registered

Marketed Breast Cancer Immunotherapies Clinical Insight

Therapeutic Approaches To Breast Cancer Immunotherapy

8.1 Monotherapeutic Approaches

8.2 Combination Therapy Approach

8.2.1 Combination Of Targeted Therapy and Endocrine Therapy

8.2.2 Combination With Immunotherapy

8.2.3 Combination Strategies That Include Triple Agents

New Immunotherapeutic Approaches In Trials For Breast Cancer Treatment

9.1 Emerging Molecular Targets For CAR T Cell Immunotherapy

9.2 Bispecific Antibodies

9.3 Vaccine Based Therapy

9.4 Oncolytic Viruses

9.5 Immunotherapy with Tumor Infiltrating Lymphocytes (TILs)

9.6 Cytokine Therapy

Global Breast Cancer Immunotherapy Market Dynamics

10.1 Market Drivers

10.2 Market Challenges

Competitive Landscape

11.1 Roche

11.2 Genentech

11.3 Amgen

11.4 Antibody Therapeutics

11.5 Pfizer

11.6 Merck

11.7 Novartis

11.8 Bristol-Myers Squibb

11.9 EirGenix

11.10 Prestige BioPharma

11.11 Novartis Oncology

11.12 Protheragen

11.13 Merck

11.14 LeadArtis

11.15 Mayo Clinic

11.16 Biocad

11.17 Therabest Korea

11.18 EpiThany

11.19 AstraZeneca

11.20 PACT Pharma

11.21 Xuanzhu Biopharmaceutical

11.22 Samsung Bioepis

11.23 Shanghai Novamab Biopharmaceuticals

11.24 ImmunityBio

Figure 1-1: Conventional Treatment Strategies Used for Breast Cancer

Figure 1-2: Classification of Immunotherapy

Figure 1-3: Different Immunotherapeutic Approaches

Figure 1-4: Majorly used current biomarkers for Breast Cancer

Figure 1-5: Emerging and Novel Biomarkers for Breast Cancer

Figure 2-1: Global – Breast Cancer immunotherapy Market Sales (US$ Billion), 2019 –

2023

Figure 2-2: Global – Breast Cancer immunotherapy Market Quarterly Sales (US$

Billion)’ 2022

Figure 2-3: Global – Breast Cancer immunotherapy Market By Drug (US$ Million),

Q1’2023

Figure 2-4: Global – Breast Cancer immunotherapy Market By Drug (US$ Million),

2022

Figure 2-5: US – Breast Cancer immunotherapy Market (US$ Billion)’ 2019 - 2023

Figure 2-6: US – Breast Cancer immunotherapy Market By Drug (US$ Million),

Q1’2023

Figure 2-7: US – Breast Cancer immunotherapy Market By Drug (US$ Million), 2022

Figure 2-8: Europe – Breast Cancer immunotherapy Market (US$ Million)’ 2019 –

2023

Figure 2-9: Europe – Breast Cancer immunotherapy Market By Drug (US$ Million),

Q1’2023

Figure 2-10: Europe – Breast Cancer immunotherapy Market By Drug (US$ Million),

2022

Figure 2-11: Global – Breast Cancer immunotherapy Market Sales (US$ Billion), 2023

- 2028

Figure 3-1: US – Share of Breast Cancer Cases In Total Cancer Cases, 2022

Figure 3-2: US – Reimbursement System

Figure 3-3: UK – Share of Breast Cancer Cases In Total Cancer Cases, 2020

Figure 3-4: UK – Key Reimbursement Stakeholders

Figure 3-5: Canada – Share of Breast Cancer Cases In Total Cancer Cases, 2020

Figure 3-6: Canada – Drug Reimbursement Process

Figure 3-7: Europe – Share of Breast Cancer Cases In Total Cancer Cases, 2020

Figure 3-8: Germany – Reimbursement Of Drugs

Figure 3-9: France – Drug Pricing and Reimbursement Process

Figure 3-10: Italy – Drug Pricing and Reimbursement Process

Figure 3-11: Spain – Pricing and Reimbursement Process

Figure 3-12: Poland – Stages Of Reimbursement Decision Making Process

Figure 3-13: Australia – Drug Payment Process

Figure 3-14: China – Share of Breast Cancer Cases In Total Cancer Cases, 2020

Figure 3-15: China – Negotiation Process for National Reimbursement Drug List

(NRLD)

Figure 3-16: Japan – Share of Breast Cancer Cases In Total Cancer Cases, 2020

Figure 3-17: Japan – Reimbursement Process For Public Insured Medical Services

Figure 3-18: South Korea – Share of Breast Cancer Cases In Total Cancer Cases,

2020

Figure 3-19: South Korea – Flow Of Reimbursement Decision making For New Drug

Figure 4-1: Global – Keytruda Annual Sales (US$ Million), 2019 – 2023

Figure 4-2: Global – Keytruda Quarterly Sales (US$ Million), 2022

Figure 4-3: US – Keytruda Annual Sales (US$ Million), 2019 – 2023

Figure 4-4: US – Keytruda Quarterly Sales (US$ Million), 2022

Figure 4-5: US - Keytruda Price per Unit and per Vial for 25mg/mL Intravenous

Solution (US$), May’2023

Figure 4-6: Keytruda – List Price of a Supply for 3 and 6 Weeks (US$), May’2023

Figure 4-7: Keytruda – Cost of Treatment for Different Administration Schedules,

May’2023

Figure 4-8: UK - Keytruda Price per 100mg/4mL Intravenous Solution, May’2023

Figure 4-9: Keytruda – Patent Expiration Year

Figure 4-10: Global – Perjeta Annual Sales (US$ Million), 2019 – 2023

Figure 4-11: Global – Perjeta Quarterly Sales (US$ Million), 2022

Figure 4-12: US – Perjeta Annual Sales (US$ Million), 2019 – 2023

Figure 4-13: US – Perjeta Quarterly Sales (US$ Million), 2022

Figure 4-14: Europe – Perjeta Annual Sales (US$ Million), 2019 – 2023

Figure 4-15: Europe – Perjeta Quarterly Sales (US$ Million), 2022

Figure 4-16: Japan – Perjeta Annual Sales (US$ Million), 2019 – 2023

Figure 4-17: Japan – Perjeta Quarterly Sales (US$ Million), 2022

Figure 4-18: US – Perjeta per Unit and Price for 420mg/14mL Intravenous Solution

(US$), May’2023

Figure 4-19: Perjeta – Total Cost Of Treatment Cycle (US$), May’2023

Figure 4-20: UK – Perjeta Price per Vial of 420mg/14mL, May’2023

Figure 4-21: Perjeta – Patent Filing Year v/s Expiration Year – US, Canada and

Australia

Figure 4-22: Global – Kadcyla Annual Sales (US$ Million), 2019 – 2023

Figure 4-23: Global – Kadcyla Quarterly Sales (US$ Million), 2022

Figure 4-24: US – Kadcyla Annual Sales (US$ Million), 2019 – 2023

Figure 4-25: US – Kadcyla Quarterly Sales (US$ Million), 2022

Figure 4-26: Europe – Kadcyla Annual Sales (US$ Million), 2019 – 2023

Figure 4-27: Europe – Kadcyla Quarterly Sales (US$ Million), 2022

Figure 4-28: Japan – Kadcyla Annual Sales (US$ Million), 2019 – 2023

Figure 4-29: Japan – Kadcyla Quarterly Sales (US$ Million), 2022

Figure 4-30: US – Kadcyla per Unit and Price (US$) For 1 Powder Injection, May’2023

Figure 4-31: Kadcyla – Cost of Treatment for 100mg and 160mg of Intravenous

Powder, May’2023

Figure 4-32: UK - Kadcyla Price per 180mg and 160mg Vial, May’2023

Figure 4-33: Kadcyla – Patent Expiration Year – US v/s UK

Figure 4-34: Global – Phesgo Annual Sales (US$ Million), 2020 – 2023

Figure 4-35: Global – Phesgo Quarterly Sales (US$ Million), 2022

Figure 4-36: US – Phesgo Annual Sales (US$ Million), 2019 – 2023

Figure 4-37: US – Phesgo Quarterly Sales (US$ Million), 2022

Figure 4-38: Europe – Phesgo Annual Sales (US$ Million), 2019 – 2023

Figure 4-39: Europe – Phesgo Quarterly Sales (US$ Million), 2022

Figure 4-40: US – Phesgo Price per Unit for 10mL of 20,000 Units Phesgo

Subcutaneous Injection (US$), May’2023

Figure 4-41: US – Phesgo Price per Unit for 15mL of 30,000 Units Phesgo

Subcutaneous Injection (US$), May’2023

Figure 4-42: Phesgo – Cost of Treatment Cycle (US$), May’2023

Figure 4-43: UK – Phesgo Price per Unit for 10mL of 600mg/600mg Phesgo

Subcutaneous Injection, May’2023

Figure 4-44: UK – Phesgo Price per Unit for 15mL of 1200mg/600mg Phesgo

Subcutaneous Injection, May’2023

Figure 4-45: Phesgo – Patent Approval and Expiration Year

Figure 4-46: Global – Trodelvy Annual Sales (US$ Million), 2021 - 2023

Figure 4-47: Global – Trodelvy Quarterly Sales (US$ Million), 2022

Figure 4-48: US – Trodelvy Annual Sales (US$ Million), 2021 –2023

Figure 4-49: US – Trodelvy Quarterly Sales (US$ Millions), 2022

Figure 4-50: Europe – Trodelvy Annual Sales (US$ Million), 2021 – 2023

Figure 4-51: Europe – Trodelvy Quarterly Sales (US$ Millions), 2022

Figure 4-52: Trodelvy - Per Unit and Price for 180mg of Intravenous Powder (US$),

May’2023

Figure 4-53: Trodelvy – Cost of Treatment Cycle (US$), May’2023

Figure 4-54: UK - Trodelvy Price per 180mg Vial Powder, May’2023

Figure 4-55: Trodelvy – US v/s UK Patent Expiration Year

Figure 4-56: Global – Herceptin Annual Sales (US$ Million), 2019 – 2023

Figure 4-57: Global – Herceptin Quarterly Sales (US$ Million), 2022

Figure 4-58: US – Herceptin Annual Sales (US$ Millions), 2019 – 2023

Figure 4-59: US – Herceptin Quarterly Sales (US$ Million), 2022

Figure 4-60: Europe – Herceptin Annual Sales (US$ Million), 2019 – 2023

Figure 4-61: Europe - Herceptin Quarterly Sales (US$ Million), 2022

Figure 4-62: Japan – Herceptin Annual Sales (US$ Million), 2019 - 2023

Figure 4-63: Japan – Herceptin Quarterly Sales (US$ Million), 2022

Figure 4-64: US – Herceptin per Unit and Price for 150mg Intravenous Powder For

Injection (US$)

Figure 4-65: Herceptin – Cost of Treatment (Schedule 1) (US$), May’2023

Figure 4-66: Herceptin – Cost of Treatment (Schedule 1) (US$), May’2023

Figure 4-67: Herceptin – Cost of Treatment for Metastatic HER2 Overexpressing

Breast Cancer (US$), May’2023

Figure 4-68: UK – Herceptin Price per Vial for 150mg Powder, May’2023

Figure 4-69: Herceptin - Patent Filing Year v/s Expiration Year – US and Canada

Figure 4-70: Global – Enhertu Annual Sales (US$ Million), 2020 – 2023

Figure 4-71: Global – Enhertu Quarterly Sales (US$ Million), 2022

Figure 4-72: US – Enhertu Annual Sales (US$ Million), 2020 – 2023

Figure 4-73: US – Enhertu Quarterly Sales (US$ Million), 2022

Figure 4-74: EU – Enhertu Annual Sales (US$ Million), 2020 – 2023

Figure 4-75: EU – Enhertu Quarterly Sales (US$ Million), 2022

Figure 4-76: Japan – Enhertu Annual Sales (US$ Million), 2020 – 2023

Figure 4-77: Japan – Enhertu Quarterly Sales (US$ Million), 2022

Figure 4-78: US - Enhertu per Unit and Price for 100 mg Of Intravenous Powder (US$)

Figure 4-79: UK– Enhertu Price per 100mg Powder, May’2023

Figure 4-80: Enhertu – Cost of Treatment With 100mg intravenous Powder,

May’2023

Figure 4-81: Margenza – Research and Development Annual Expense (US$ Million),

2020 - 2022

Figure 4-82: Margenza –Research and Development Quarterly Expense (US$ Million),

2022

Figure 4-83: US - Margenza Price per Unit for 25mg/mL Intravenous Solution (US$),

May’2023

Figure 4-84: Margenza – Cost of Treatment with Different Volumes of Intravenous

Solution, May’2023

Figure 4-85: Global – Tecentriq Annual Sales (US$ Million), 2019 – 2023

Figure 4-86: Global – Tecentriq Quarterly Sales (US$ Million), 2022

Figure 4-87: US – Tecentriq Annual Sales (US$ Million), 2019 – 2023

Figure 4-88: US – Tecentriq Quarterly Sales (US$ Million), 2022

Figure 4-89: Europe– Tecentriq Annual Sales (US$ Million), 2019 – 2023

Figure 4-90: Europe – Tecentriq Quarterly Sales (US$ Million), 2022

Figure 4-91: Japan – Tecentriq Annual Sales (US$ Million), 2019 – 2023

Figure 4-92: Japan – Tecentriq Quarterly Sales (US$ Million), 2022

Figure 4-93: US - Tecentriq Price per Unit for 840mg/14mL and 1200mg/20mL of

Intravenous Solution (US$), May’2023

Figure 4-94: UK – Tecentriq Price per Unit for 840mg/14mL and 1200mg/20mL of

Intravenous Solution, May’2023

Figure 4-95: Tecentriq – Global Patent Approval and Expiration Year

Figure 4-96: Global – Avastin Annual Sales (US$ Million), 2019 – 2023

Figure 4-97: Global - Avastin Quarterly Sales (US$ Million), 2022

Figure 4-98: US – Avastin Annual Sales (US$ Million), 2019 – 2023

Figure 4-99: US– Avastin Quarterly Sales (US$ Million), 2022

Figure 4-100: Europe – Avastin Annual Sales (US$ Million), 2019 – 2023

Figure 4-101: Europe – Avastin Quarterly Sales (US$ Million), 2022

Figure 4-102: Japan – Avastin Annual Sales (US$ Million), 2019 -2023

Figure 4-103: Japan – Avastin Quarterly Sales (US$ Million), 2022

Figure 4-104: US - Avastin Price per Unit for 25mg/mL of Intravenous Solution

(US$), May’2023

Figure 4-105: UK – Avastin Price per Unit for Different Concentrations of Infusion

Vial, May’2023

Figure 5-1: Global - Breast Cancer immunotherapy Drug Clinical Trials By

Biomarker, 2023

Figure 5-2: Global - Breast Cancer immunotherapy Drug Clinical Trials By Company,

2023

Figure 5-3: Global - Breast Cancer immunotherapy Drug Clinical Trials By Country,

2023

Figure 5-4: Global - Breast Cancer immunotherapy Drug Clinical Trials By Patient

Segment, 2023

Figure 5-5: Global - Breast Cancer immunotherapy Drug Clinical Trials By Phase,

2023

Figure 8-1: Available Monotherapeutic Approaches

Figure 8-2: Available Combinational Therapies

Figure 9-1: Emerging Immunotherapeutic Approaches Currently In Trial

Figure 10-1: Current Market Drivers

Figure 10-2: Current Market Challenges

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Breast Cancer Immunotherapy Market and Clinical Trials Forecast 2028

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected